Publications - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.

Hunt et al. • 2012 • Bioorg Med Chem Lett. 2012;22(24):7376-80.

Mifepristone treatment of olanzapine-induced weight gain in healthy men.

Gross et al. • 2009 • Adv Ther. 2009;26(10):959-69.

Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.

Gross et al. • 2010 • Obesity (Silver Spring). 2010;18(12):2295-300.

The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.

Beebe et al. • 2006 • Behav Brain Res. 2006;171(2):225-9.

Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.

Belanoff et al. • 2011 • Eur J Pharmacol. 2011;655(1-3):117-20.

Selective glucocorticoid receptor (GR-II) antagonist reduces body weight gain in mice.

Asagami et al. • 2011 • J Nutr Metab. 2011;2011:235389.

Minireview: nuclear receptors and breast cancer.

Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.

Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats.

Beaudry et al. • 2014 • PLoS One. 2014;9(3):e91248.

Glucocorticoid antagonism limits adiposity rebound and glucose intolerance in young male rats following the cessation of daily exercise and caloric restriction.

Teich et al. • 2016 • Am J Physiol Endocrinol Metab. 2016;311(1):E56-68.

Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation.

van den Heuvel et al. • 2016 • Br J Pharmacol. 2016;173(11):1793-804.